By David | Biotech News Today
Many biotech companies have a promising medicine but no factory to make it. Building a manufacturing plant can take years and cost a very large amount of money. This is where contract partners come in. If you have seen the terms “biotech CMO” or “CDMO” in industry news, this guide explains what they mean, what these companies do, and why they matter for modern medicine.
What Is a CMO?
A CMO (Contract Manufacturing Organization) is a company that manufactures a drug or biologic for another company under a contract. The company that owns the product, often called the sponsor, hires the CMO to produce it instead of building its own facility.
A biotech CMO is simply a CMO that specialises in biologic products, such as antibodies, proteins, vaccines, or gene therapies, rather than chemical tablets. These products need living cells, special equipment, and strict controls, so not every manufacturer can make them.
What Is a CDMO?
A CDMO (Contract Development and Manufacturing Organization) does everything a CMO does and also helps with development. That means a CDMO can help a sponsor design the manufacturing process, test it, scale it up, and then produce the medicine for clinical trials and for the market.
| Term | Full form | Main role |
|---|---|---|
| CMO | Contract Manufacturing Organization | Manufactures a product that is already defined |
| CDMO | Contract Development and Manufacturing Organization | Develops the process and manufactures the product |
| CRO | Contract Research Organization | Runs research and clinical trials, not manufacturing |
In everyday news, people often use CMO and CDMO as if they are the same. The main difference is that a CDMO offers development support as well.
Why Do Biotech Companies Use CDMOs?
Biologic manufacturing is difficult and expensive. A CDMO offers several practical benefits:
- Lower upfront cost. The sponsor does not need to build and equip a plant before the product is proven.
- Speed. Experienced teams and existing facilities can shorten the time to clinical supply.
- Expertise. CDMOs work with many products and have specialist knowledge in cell culture, purification, and testing.
- Flexibility. A small company can scale production up or down as trial results change.
- Capacity. Large pharma companies also use CDMOs when their own plants are full.
To understand what the factory work involves, read our guide on how biologic drugs are made.
Services a CDMO Typically Offers
The exact list differs by company, but most biologics CDMOs cover some or all of these areas:
| Service | What it involves |
|---|---|
| Cell line development | Creating a stable cell line that produces the target protein |
| Process development | Designing and optimising how the product is grown and purified |
| Analytical development | Building tests that measure purity, strength, and consistency |
| Clinical manufacturing | Making batches for early and late-stage trials |
| Commercial manufacturing | Producing the approved medicine at scale |
| Fill-finish | Filling the final drug into vials or syringes under sterile conditions |
| Regulatory support | Helping prepare the documents needed for approval |
mAb CDMO: Monoclonal Antibody Manufacturing
A mAb CDMO focuses on monoclonal antibodies, one of the most common types of biologic medicine. These large proteins are usually produced in mammalian cells, such as Chinese hamster ovary (CHO) cells, grown in large bioreactors. After growth, the antibody is separated and purified through several filtration and chromatography steps.
Because antibodies are so widely used in cancer, autoimmune disease, and other conditions, mAb manufacturing capacity is in high demand. Sponsors often choose a mAb CDMO based on its experience with similar molecules, its available bioreactor sizes, and its track record with regulators.
Injectables CDMO: Sterile Fill-Finish
Most biologics are given by injection, so the final product must be sterile. An injectables CDMO specialises in filling drugs into vials, prefilled syringes, or cartridges using aseptic techniques, where the product is protected from contamination during every step.
This stage is delicate. Biologic molecules can be damaged by heat, shaking, or poor formulation, so the filling process must be carefully controlled and tested. Many CDMOs offer fill-finish as a separate service or as part of an end-to-end package.
Genetic Medicine CDMO: Gene and Cell Therapy Support
A genetic medicine CDMO supports newer types of treatment, such as gene therapy and RNA-based medicines. The raw materials and methods are quite different from antibody production. Depending on the product, the work may involve:
- Producing plasmid DNA used as a starting material
- Manufacturing viral vectors, such as adeno-associated virus (AAV), that carry a gene into cells
- Making mRNA or other nucleic acid medicines
- Handling cell therapies where the patient’s own cells may be processed
This area is still developing, and capacity and specialised know-how are limited, which makes the choice of partner especially important. For background on the wider field, see our guide on biotech medicine.
Comparing the Main CDMO Types
| CDMO type | Typical product | Key focus |
|---|---|---|
| mAb CDMO | Monoclonal antibodies | Cell culture and purification at scale |
| Injectables CDMO | Sterile liquid or powder drugs | Aseptic fill-finish and packaging |
| Genetic medicine CDMO | Gene therapies, mRNA, cell therapies | Viral vectors, plasmids, and nucleic acids |
Quality and Regulation
A CDMO must follow current Good Manufacturing Practice (cGMP) rules, which set minimum standards for how medicines are made, tested, and documented. The U.S. Food and Drug Administration explains cGMP requirements on its CGMP regulations page.
Even when a CDMO makes the product, the sponsor stays responsible for its quality. For that reason, sponsors and CDMOs usually sign a written quality agreement that explains who does what, and sponsors audit their partners regularly.
Risks and How to Manage Them
Outsourcing is not risk-free. Common challenges include:
- Technology transfer. Moving a process from one site to another can cause small differences that need careful testing.
- Supply dependence. If the CDMO has a problem, the sponsor’s supply may be delayed.
- Intellectual property. Contracts must clearly protect the sponsor’s know-how.
- Communication. Different time zones and teams can slow decisions.
Good planning, clear contracts, and regular quality reviews reduce most of these risks.
How to Choose a CDMO
When comparing partners, sponsors usually look at:
- Experience with the same type of molecule or therapy
- Inspection history and quality record
- Available capacity and scale
- Range of services in one place
- Communication and project management
- Cost and timeline
These points also help students understand what makes one CDMO stronger than another.
CDMOs, Biotech and Pharma
CDMOs are one reason the line between small biotech firms and large drug makers is blurring. A small company can reach the clinic without owning a plant, while a large company can add capacity quickly. You can read more about this in our article on biotech vs pharma, and learn the basics of the medicines themselves in our guide to biopharmaceuticals.
Frequently Asked Questions
What does CDMO stand for? Contract Development and Manufacturing Organization.
What is the difference between a CMO and a CDMO? A CMO manufactures a product under contract. A CDMO also helps develop the manufacturing process.
What is a biotech CMO? It is a contract manufacturer that makes biologic products, such as antibodies, proteins, or gene therapies.
Why do small biotech companies use CDMOs? Building a plant is slow and costly, so a CDMO lets them make clinical supply without that investment.
Who is responsible for quality when a CDMO makes the drug? The sponsor remains responsible for product quality, even though the CDMO does the manufacturing.
Final Thoughts
A CDMO is a partner that helps move a medicine from the lab to patients by developing and manufacturing it. Whether the focus is monoclonal antibodies, sterile injectables, or gene therapies, these companies play a central role in how modern biologics reach the market. Understanding them gives students a clearer view of how the biotech industry really works.
This article is for educational purposes only and is not medical or investment advice.
2 Pingbacks